Making a Healthy Difference Through Partnerships with Federally Qualified Health Centers

Federally Qualified Health Centers (FQHC) are community-based healthcare providers that receive funding to offer primary-care services in low-income and underserved communities.

On May 18th, 2022, Yuvo Health announced a partnership with four FQHCs. This partnership will enable them to expand these FQHCs reach to even more individuals. Cesar Herrera, CEO & Co-Founder of Yuvo Health, spoke with I Don’t Care host Kevin Stevenson  about this exciting opportunity.

As Herrera explained, Yuvo Health provides administrative and technology wrap-around services to support federally qualified health centers to enable their transition to value-based care. Rural and hyper-urban areas are two concentrations where FQHCs play a vital role in supporting the communities.

Yuvo Health’s mission is personal as well as professional. Herrera was an FQHC patient growing up. His first-hand experience of the importance these centers provide to the community gave him an understanding of what happens to a society that doesn’t have equitable access to primary healthcare.

In NYC, where Yuvo Health is based, most private practice doctors don’t accept any insurance. This exclusivity closes the door to many patients who cannot afford private care and magnifies the problem in underserved communities where options are limited. That’s why Yuvo’s announcement is welcome news.

“We’ve brought on our first set of FQHC partners with our model launched in downstate NY,” Herrera said. “What Yuvo is, is an IPA and an MSO model. It enables us to establish value-based contracts on behalf of our FQHC partners with managed care entities, and in many cases, these are contracts that our FQHC partners would not be able to establish on their own.”

These first four FQHC partners represent a diverse set of the patient population representing the five boroughs of NYC and Long Island, and roughly 40,000 Medicaid lives flowing through their centers every year.

More Like This Story:

Tearing Down the Barrier of Prior Authorization Through Automation

How To Navigate the American Healthcare System

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More